Different by design
Like much of the work we do at Calico, our development approach is different by design. Our efforts focus on identifying new targets — that are not currently being pursued by many others — based on our evolving understanding of the biology of aging and age-related diseases.
We’re translating that research into first-in-class compounds to target diseases commonly linked with aging. In some cases, our targets are predicted to also target aging more generally, thus having the potential to extend the overall human healthspan.
Calico Stories
The Integrated Stress Response (ISR) is a conserved signaling pathway across species and an important area of focus for Calico because of its possible link to many age-related…
Focused on patient benefit
We believe that focusing on new areas of biology and making big leaps in science and then translating these efforts into drug candidates for potential clinical development will lead to patient benefit. Our approach has yielded a portfolio comprised of more than 20 early- and late-stage preclinical compounds in cancer, neurological diseases, and tissue homeostasis and repair.
LEARN MORE ABOUT OUR CLINICAL TRIALS
Born of collaboration and partnership
Our clinical development efforts are powered by collaboration, both within Calico and with our external partners. For example, we work closely with the Broad Institute of MIT and Harvard on drug discovery programs, most notably a target screening program that has yielded a number of promising immunotherapy cancer targets we are actively pursuing.
To govern our programs with end-to-end control, Calico is developing robust internal capabilities across the entire pipeline. From initial target identification and drug discovery to late-stage clinical development, our expanded capacity provides us with the essential optionality to manage programs in-house, or strategically partner when it creates a mutually beneficial structure that augments the strengths of both parties.